Biotechnology

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Australian biopharma Immuron reports strong global sales for its travel supplement and launches a new IBS product, navigating industry mergers and digital trends.

Veteran drug discoverer Dr. Adam Davenport joins as CSO, bringing expertise in cutting-edge modalities to accelerate client pipelines in a competitive market.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.

With a new CEO and promising data, Emmecell aims to replace corneal transplants with its magnetic cell delivery platform. But can it win in a competitive market?

Genmab's antibody drug epcoritamab is the first of its kind to slow cancer progression in a Phase 3 trial for R/R DLBCL, offering a new path for patients.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

South Korean researchers created a 'Janus' patch that bonds to wet tissue in seconds, preventing dangerous leaks and complications in neurosurgery.

Vaximm appoints Sébastien Wieckowski as CSO, leveraging his data science expertise to advance its oral cancer vaccine platform at a pivotal clinical stage.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

A new partnership aims to revolutionize chronic care by letting patients self-administer large-volume biologics safely in their own homes.

Results in Nature Medicine reveal an immunotherapy that may stop cancer before it starts in high-risk Lynch Syndrome carriers, heralding a new era of prevention.

In a strategic move to enhance domestic drug production, Agno Pharma has acquired a key Oregon manufacturing site, signaling major industry consolidation.

With a new $16.5M loan, Ocular Science is poised to expand its role in compounded eye medications, meeting the needs of an aging population.

Backed by Canada's life sciences engine adMare, new biotech firm Ocythera is advancing a unique non-retinoid therapy for debilitating bone disorders.

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

With the appointment of agency veteran Raffi Siyahian, VaultBio aims to bridge the gap between life sciences strategy and real-world market execution.

Merck's former R&D IT head Matt Studney joins TetraScience, a move highlighting biopharma's critical pivot from fragmented data to industrial-scale AI.

A new partnership aims to make life-saving cancer and anti-infective drugs stable at room temperature, revolutionizing global access and sustainability.